Laura Finn1, Andrew Dalovisio1,2, James Foran3. 1. Division of Hematology and Bone Marrow Transplant, Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA. 2. The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA. 3. Division of Hematology and Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL.
Abstract
BACKGROUND: Even though acute myeloid leukemia (AML) occurs most commonly in adults ≥60 years, the treatment of AML in older patients remains a significant challenge. METHODS: We reviewed the current literature regarding patient assessment tools, treatment options, and current therapies in clinical trial for patients with AML who are ≥60 years. RESULTS: Our approach to the older patient with AML is evolving with better understanding of the unique disease epidemiology in this population and the development of tools to assess individual patient functional status, including grading systems for comorbidities, geriatric assessment tools, and measurements of frailty. Almost all older patients will benefit from therapy, whether intensive curative therapy, such as allogeneic stem cell transplant that should be considered whenever possible, or low-intensity therapy that should be offered with concurrent palliative care at diagnosis to improve patient survival and quality of life. To achieve the improved survival demonstrated in younger adults, older patients should also be considered for clinical trial enrollment as more studies are being designed to specifically target this unique patient population. CONCLUSION: Older patients with AML are candidates for and benefit from the entire spectrum of AML therapy, including intense chemotherapy, allogeneic stem cell transplant, and clinical trial participation after thorough patient assessment. Older patients with AML would benefit from increased clinical trial enrollment and early inclusion of palliative medicine.
BACKGROUND: Even though acute myeloid leukemia (AML) occurs most commonly in adults ≥60 years, the treatment of AML in older patients remains a significant challenge. METHODS: We reviewed the current literature regarding patient assessment tools, treatment options, and current therapies in clinical trial for patients with AML who are ≥60 years. RESULTS: Our approach to the older patient with AML is evolving with better understanding of the unique disease epidemiology in this population and the development of tools to assess individual patient functional status, including grading systems for comorbidities, geriatric assessment tools, and measurements of frailty. Almost all older patients will benefit from therapy, whether intensive curative therapy, such as allogeneic stem cell transplant that should be considered whenever possible, or low-intensity therapy that should be offered with concurrent palliative care at diagnosis to improve patient survival and quality of life. To achieve the improved survival demonstrated in younger adults, older patients should also be considered for clinical trial enrollment as more studies are being designed to specifically target this unique patient population. CONCLUSION: Older patients with AML are candidates for and benefit from the entire spectrum of AML therapy, including intense chemotherapy, allogeneic stem cell transplant, and clinical trial participation after thorough patient assessment. Older patients with AML would benefit from increased clinical trial enrollment and early inclusion of palliative medicine.
Authors: Areej R El-Jawahri; Gregory A Abel; David P Steensma; Thomas W LeBlanc; Amir T Fathi; Timothy A Graubert; Daniel J DeAngelo; Martha Wadleigh; Karen K Ballen; Julia E Foster; Eyal C Attar; Philip C Amrein; Andrew M Brunner; Richard M Stone; Jennifer S Temel Journal: Cancer Date: 2015-04-29 Impact factor: 6.860
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Mohamed L Sorror; Brent R Logan; Xiaochun Zhu; J Douglas Rizzo; Kenneth R Cooke; Philip L McCarthy; Vincent T Ho; Mary M Horowitz; Marcelo C Pasquini Journal: Biol Blood Marrow Transplant Date: 2015-04-07 Impact factor: 5.742
Authors: Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: Sherif S Farag; Kati Maharry; Mei-Jie Zhang; Waleska S Pérez; Stephen L George; Krzysztof Mrózek; John DiPersio; Donald W Bunjes; Guido Marcucci; Maria R Baer; Mitchell Cairo; Edward Copelan; Corey S Cutler; Luis Isola; Hillard M Lazarus; Mark R Litzow; David I Marks; Olle Ringdén; David A Rizzieri; Robert Soiffer; Richard A Larson; Martin S Tallman; Clara D Bloomfield; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2011-06-21 Impact factor: 5.742
Authors: Margaret R O'Donnell; Martin S Tallman; Camille N Abboud; Jessica K Altman; Frederick R Appelbaum; Daniel A Arber; Vijaya Bhatt; Dale Bixby; William Blum; Steven E Coutre; Marcos De Lima; Amir T Fathi; Melanie Fiorella; James M Foran; Steven D Gore; Aric C Hall; Patricia Kropf; Jeffrey Lancet; Lori J Maness; Guido Marcucci; Michael G Martin; Joseph O Moore; Rebecca Olin; Deniz Peker; Daniel A Pollyea; Keith Pratz; Farhad Ravandi; Paul J Shami; Richard M Stone; Stephen A Strickland; Eunice S Wang; Matthew Wieduwilt; Kristina Gregory; Ndiya Ogba Journal: J Natl Compr Canc Netw Date: 2017-07 Impact factor: 11.908
Authors: Daniel J Weisdorf; Heather R Millard; Mary M Horowitz; Parvinder S Hyare; Richard Champlin; Vincent Ho; Marco Mielcarek; Andrew Rezvani; Keith Stockerl-Goldstein; Hanna J Khoury; Marcos De Lima; Wael Saber; Brenda Sandmaier; Mei Jie Zhang; Mary Eapen Journal: Cancer Date: 2017-01-24 Impact factor: 6.860
Authors: J Reiffers; F Huguet; A M Stoppa; L Molina; G Marit; M Attal; J A Gastaut; M Michallet; G Lepeu; A Broustet; J Pris; D Maraninchi; D Hollard; C Fabères; M Mercier; P Hurteloup; P Danel; Z Tellier; P Berthaud Journal: Leukemia Date: 1996-03 Impact factor: 11.528
Authors: F Mandelli; M C Petti; A Ardia; N Di Pietro; F Di Raimondo; F Ganzina; E Falconi; E Geraci; S Ladogana; R Latagliata Journal: Eur J Cancer Date: 1991 Impact factor: 9.162
Authors: Maro Ohanian; Uri Rozovski; Rashmi Kanagal-Shamanna; Lynne V Abruzzo; Sanam Loghavi; Tapan Kadia; Andrew Futreal; Kapil Bhalla; Zhuang Zuo; Yang O Huh; Sean M Post; Peter Ruvolo; Guillermo Garcia-Manero; Michael Andreeff; Steven Kornblau; Gautam Borthakur; Peter Hu; L Jeffrey Medeiros; Koichi Takahashi; Marisa J Hornbaker; Jianhua Zhang; Graciela M Nogueras-González; Xuelin Huang; Srdan Verstovsek; Zeev Estrov; Sherry Pierce; Farhad Ravandi; Hagop M Kantarjian; Carlos E Bueso-Ramos; Jorge E Cortes Journal: Leuk Lymphoma Date: 2018-05-09
Authors: Luis Enrique Colunga-Lozano; Fernando Kenji Nampo; Arnav Agarwal; Pinkal Desai; Mark Litzow; Mikkael A Sekeres; Gordon H Guyatt; Romina Brignardello-Petersen Journal: PLoS One Date: 2022-02-02 Impact factor: 3.240
Authors: Ravendra Garg; Kevin J H Allen; Wojciech Dawicki; Eileen M Geoghegan; Dale L Ludwig; Ekaterina Dadachova Journal: Cancer Med Date: 2020-12-21 Impact factor: 4.452